BioCentury
ARTICLE | Company News

Genta licenses antisense IP to Atugen

January 29, 2001 8:00 AM UTC

GNTA non-exclusively licensed its patents covering the inhibition of protein synthesis using antisense oligonucleotides to Atugen (Berlin, Germany). GNTA will receive an upfront cash payment, yearly c...